Amide Technologies is a pioneering player in the information technology space, focused on revolutionizing peptide manufacturing. Founded in 2016, the company's novel manufacturing platform, developed at MIT, enables on-demand complex peptide manufacturing at an unprecedented speed. Their slogan, "Peptide sourcing shouldn't stand in the way of discovery," encapsulates their mission to bridge the gap between traditional solid phase peptide synthesis and biological expression. Their latest milestone includes a significant $7.50M Series A investment which occurred on 28 July 2023. The investment was led by The Engine and Forcefield Ventures, showcasing confidence from prominent investors in the company's vision and potential to transform the landscape of peptide drug design. Headquartered in the United States, Amide Technologies is empowering scientists on the cutting edge of peptide drug discovery, offering a promising avenue for venture capital to explore.
No recent news or press coverage available for Amide Technologies.